Study update: One third of the patients have been recruited in the TECVI-1 trial
An important milestone in the TECVI-1 study was reached, as one third of the patients have now been recruited.
The study aims to evaluate the safety of personalized tissue engineered veins (P-TEV) with valves implanted in patients with severe chronic venous insufficiency (CVI).
More on CVI: https://verigraft.com/therapeutic-areas/